| Name | Title | Contact Details |
|---|---|---|
Bryon Wornson |
Vice President Talent | Profile |
Ron Bentsur |
Chief Executive Officer | Profile |
Drawing inspiration from the pioneering women and community leaders who helped establish the Hospital in 1875, Lawrence General has remained focused throughout its history to serve the community as a private, not-for-profit acute care hospital. The Hospital’s physicians and caregivers offer treatment to all patients, regardless of race, color, creed, or national origin. Every member of the clinical team works to assure the quality and level of care the Hospital provides, supporting community education and research to improve the health of the Merrimack Valley and its citizens.
Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of end stage kidney disease (ESKD). Pathalys` initial asset is upacicalcet, a novel calcimimetic with the potential to improve the treatment of SHPT in hemodialysis patients. Beyond upacicalcet, Pathalys continues to identify other high priority needs and potential solutions for patients with ESKD. Pathalys is headquartered in Research Triangle Park, North Carolina.
DPT is a contract development and manufacturing organization specializing in semi-solid and liquid dosage forms. Recognized globally for technical expertise and virtually unlimited manufacturing capabilities, DPT is the industry source for fully
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological cancers.
LTS offers a wealth of experience in adhesive formulation and coating technology to manufacture and supply specialty laminates intermediates for many applications. Our products are tailored to our customers' needs and are targeted for use in